MEDA Says FDA Approved Dymista - Quick Facts

5/2/2012 2:35 AM ET

MEDA AB (MDABF.PK) said the U.S. Food and Drug Administration has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis, or SAR. In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment.

Anders Lönner, CEO of Meda AB, said, "...The approval of Dymista represents an important achievement for Meda's clinical development groups in the US and Europe. Meda's franchise in the allergy area is strengthened and gives opportunities for the company to grow and establish collaborations in the field. Dymista will be available in the US during the second half of 2012".

Click here to receive FREE breaking news email alerts for Meda AB and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 130 Articles

Editors Pick

HP Profit Falls Yet Tops Estimates

Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.

Worries About Fed Tapering Lead To Sell-Off On Wall Street - U.S. Commentary

Stocks showed a substantial downturn over the course of the trading day on Wednesday after seeing some strength in morning trading. Renewed worries about the Federal Reserve tapering its asset purchase program contributed to the sharp pullback by the markets. The major averages climbed off their worst levels going into the close but still ended the day firmly negative.

Fed Minutes Show Some Members Want To Scale Back QE3 This Summer

Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...